Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza
Open Access
- 1 March 2007
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 13 (3) , 449-457
- https://doi.org/10.3201/eid1303.060309
Abstract
We used a deterministic SEIR (susceptible-exposed-infectious-removed) meta-population model, together with scenario, sensitivity, and simulation analyses, to determine stockpiling strategies for neuraminidase inhibitors that would minimize absenteeism among healthcare workers. A pandemic with a basic reproductive number (R0) of 2.5 resulted in peak absenteeism of 10%. Treatment decreased peak absenteeism to 8%, while 8 weeks’ prophylaxis reduced it to 2%. For pandemics with higher R0, peak absenteeism exceeded 20% occasionally and 6 weeks’ prophylaxis reduced peak absenteeism by 75%. Insufficient duration of prophylaxis increased peak absenteeism compared with treatment only. Earlier pandemic detection and initiation of prophylaxis may render shorter prophylaxis durations ineffective. Eight weeks’ prophylaxis substantially reduced peak absenteeism under a broad range of assumptions for severe pandemics (peak absenteeism >10%). Small investments in treatment and prophylaxis, if adequate and timely, can reduce absenteeism among essential staff.Keywords
This publication has 18 references indexed in Scilit:
- Influenza-associated Deaths in Tropical SingaporeEmerging Infectious Diseases, 2006
- Factors that make an infectious disease outbreak controllableProceedings of the National Academy of Sciences, 2004
- Containing Pandemic Influenza with Antiviral AgentsAmerican Journal of Epidemiology, 2004
- Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study.2004
- Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and HospitalizationsArchives of internal medicine (1960), 2003
- Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trialsBMJ, 2003
- Influenza in the acute hospital settingThe Lancet Infectious Diseases, 2002
- Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trialThe Lancet, 2000
- Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human InfluenzaJAMA, 1999
- Emerging Infections: Pandemic InfluenzaEpidemiologic Reviews, 1996